• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2012-2014 年有医疗保险的新进入血液透析患者动静脉通路的临床结局。

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.

机构信息

EpidStat Institute, Ann Arbor, Michigan, USA.

Humacyte Incorporated, Morrisville, North Carolina, USA.

出版信息

Am J Nephrol. 2019;49(2):156-164. doi: 10.1159/000495355. Epub 2019 Jan 24.

DOI:10.1159/000495355
PMID:30677763
Abstract

BACKGROUND

Chronic hemodialysis requires a mode of vascular access through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter (CVC). AVF is recommended over AVG or CVC due to increased patency and decreased intervention rates for those that mature. AVG are preferred over CVC due to decreased infection and mortality risk. The aims of this study were to evaluate the lifespan of AVF and AVG in maturation, sustained access use, and abandonment.

METHODS

The United States Renal Data System (USRDS), Medicare claims, and CROWNWeb were used to identify access placements. Patients with a first end-stage renal disease (ESRD) service from January 1, 2012 to June 30, 2014 with continuous coverage with Medicare as primary payer and ≥1 AVF or AVG placed after ESRD onset were included. Maturation was defined as the first use of the access for hemodialysis recorded in CROWNWeb. Sustained access use was defined as 3 consecutive months of use without catheter placement or replacement. Accesses that were never used at any time post-placement were considered abandoned.

RESULTS

The cohort included 38,035 AVF placements and 12,789 AVG placements. Sixty-nine percent of AVF and 72% of AVG matured. Fifty-two percent of AVF and 51% of AVG achieved sustained access use. One quarter of AVF and 14% of AVG were abandoned without use as recorded in CROWNWeb.

CONCLUSION

Although considered the gold standard for vascular access, only half of AVF and AVG placements achieved sustained access use. The USRDS database has inherent limitations but provides useful clinical insight into maturation, sustained use, and abandonment.

摘要

背景

慢性血液透析需要通过动静脉瘘(AVF)、人工动静脉移植物(AVG)或中心静脉导管(CVC)建立血管通路。由于成熟后通畅率增加和干预率降低,AVF 优于 AVG 或 CVC。由于感染和死亡率降低,AVG 优于 CVC。本研究的目的是评估 AVF 和 AVG 在成熟、持续使用和废弃方面的寿命。

方法

使用美国肾脏数据系统(USRDS)、医疗保险索赔和 CROWNWeb 来确定通路的放置。纳入标准为 2012 年 1 月 1 日至 2014 年 6 月 30 日首次接受终末期肾病(ESRD)服务、持续以医疗保险为主要支付者、在 ESRD 发病后至少放置过 1 个 AVF 或 AVG 的患者。成熟定义为 CROWNWeb 中记录的第一次用于血液透析的通路使用。持续通路使用定义为连续 3 个月无导管放置或更换。任何时候都未使用过的通路被认为是废弃的。

结果

该队列包括 38035 个 AVF 放置和 12789 个 AVG 放置。69%的 AVF 和 72%的 AVG 成熟。52%的 AVF 和 51%的 AVG 实现了持续通路使用。四分之一的 AVF 和 14%的 AVG 未使用(如 CROWNWeb 中记录)而被废弃。

结论

尽管 AVF 被认为是血管通路的金标准,但只有一半的 AVF 和 AVG 放置实现了持续通路使用。USRDS 数据库存在固有局限性,但为成熟、持续使用和废弃提供了有用的临床见解。

相似文献

1
Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.2012-2014 年有医疗保险的新进入血液透析患者动静脉通路的临床结局。
Am J Nephrol. 2019;49(2):156-164. doi: 10.1159/000495355. Epub 2019 Jan 24.
2
Gender Disparities in Vascular Access Surgical Outcomes in Elderly Hemodialysis Patients.老年血液透析患者血管通路手术结局的性别差异。
Am J Nephrol. 2019;49(1):11-19. doi: 10.1159/000495261. Epub 2018 Dec 13.
3
Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare coverage.医疗保险覆盖的血液透析患者动静脉瘘和动静脉移植物置管所导致的成本。
Am J Nephrol. 2019;50(4):320-328. doi: 10.1159/000502507. Epub 2019 Aug 21.
4
Catheter Dependence After Arteriovenous Fistula or Graft Placement Among Elderly Patients on Hemodialysis.老年血液透析患者动静脉瘘或移植物置管后的导管依赖。
Am J Kidney Dis. 2021 Sep;78(3):399-408.e1. doi: 10.1053/j.ajkd.2020.12.019. Epub 2021 Feb 12.
5
Tradeoffs in Vascular Access Selection in Elderly Patients Initiating Hemodialysis With a Catheter.老年血液透析患者导管置管时血管通路选择的权衡。
Am J Kidney Dis. 2018 Oct;72(4):509-518. doi: 10.1053/j.ajkd.2018.03.023. Epub 2018 May 18.
6
Arteriovenous Vascular Access-Related Procedural Burden Among Incident Hemodialysis Patients in the United States.美国新进入血液透析患者的动静脉血管通路相关程序性负担。
Am J Kidney Dis. 2021 Sep;78(3):369-379.e1. doi: 10.1053/j.ajkd.2021.01.019. Epub 2021 Apr 20.
7
Vascular access for hemodialysis in the elderly.老年患者血液透析的血管通路。
J Vasc Surg. 2019 Feb;69(2):517-525.e1. doi: 10.1016/j.jvs.2018.05.219.
8
Assessment of Use of Arteriovenous Graft vs Arteriovenous Fistula for First-time Permanent Hemodialysis Access.评估动静脉移植物与动静脉瘘在首次永久性血液透析通路中的应用。
JAMA Surg. 2019 Sep 1;154(9):844-851. doi: 10.1001/jamasurg.2019.1736.
9
Surgical and endovascular assisted maturation procedures improve cannulation after arteriovenous fistula creation, but not after arteriovenous graft placement.手术和血管内辅助成熟程序可改善动静脉瘘创建后的血管通路建立,但对动静脉移植物置管后的效果不佳。
J Vasc Access. 2024 Sep;25(5):1649-1658. doi: 10.1177/11297298231185793. Epub 2023 Jul 8.
10
Incidence and risk factors of sepsis in hemodialysis patients in the United States.美国血液透析患者中脓毒症的发生率及危险因素。
J Vasc Surg. 2021 Mar;73(3):1016-1021.e3. doi: 10.1016/j.jvs.2020.06.126. Epub 2020 Jul 21.

引用本文的文献

1
Effect of far-infrared therapy device on arteriovenous fistula maturation and lifespan in hemodialysis patients: a randomized controlled clinical trial.远红外治疗仪对血液透析患者动静脉内瘘成熟度及使用寿命的影响:一项随机对照临床试验
Front Surg. 2023 Sep 11;10:1260979. doi: 10.3389/fsurg.2023.1260979. eCollection 2023.
2
Hemodialysis Access Type and Access Patency Loss: An Observational Cohort Study.血液透析通路类型与通路失功:一项观察性队列研究。
Kidney Med. 2022 Nov 5;5(1):100567. doi: 10.1016/j.xkme.2022.100567. eCollection 2023 Jan.
3
Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: Cost-effectiveness and budget impact analyses.
血管内与手术方式建立血液透析患者动静脉瘘的效果比较:成本效益和预算影响分析。
J Vasc Access. 2021 Jan;22(1):48-57. doi: 10.1177/1129729820921021. Epub 2020 May 19.